Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. 在 2026年8月11日 公布了什么

取自公司自己的 8-K 文件。

股价作何反应

公告在收盘后或开盘前发布，因此这里的变动是随后的那个交易日。

Hemab Therapeutics Holdings, Inc. 做什么

Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international natural history study (Glanzmann’s 360) revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week with 65% requiring a bleed-related hospital visit in the prior six months. These bleeding episodes significantly impacted patients’ mental health and quality of life, with over 80% having missed work or school, over 50% facing limitations in attending social events, and over 50% experiencing restrictions in travel. To date, there are no approved prophylactic treatment options for GT.

公司自己的描述，取自公告末尾。